PharVision Advisers’s Quanterix QTRX Stock Holding History

PharVision Advisers’s Portfolio QTRX Stock Details QTRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-13,039	Closed	-$56.3K	–	65
2026 Q2	$56.3K	Buy	+13,039	New	+$42.3K	1.06%	57
2025 Q4	–	Sell	-36,144	Closed	-$196K	–	946
2025 Q3	$196K	Buy	+36,144	New	+$192K	0.11%	523

Other funds holding QTRX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Clearstead Advisors Cleveland, Ohio $10.8B AUM 17.88% 1-Year Est. Return

Peddock Capital Advisors Braintree, Massachusetts $514M AUM 22.76% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

HUB Investment Partners Austin, Texas $5.8B AUM 24.38% 1-Year Est. Return

PharVision Advisers's QTRX Position: Q3 2026 in Review

PharVision Advisers sold out of Quanterix (QTRX) in Q3 2026, closing a stake of 13,039 shares — an estimated $56.3K sold.

PharVision Advisers first reported a position in QTRX in Q3 2025 and held it in 2 quarters. The position peaked at $196K in Q3 2025. 35 funds tracked by Wall St. Rank hold QTRX as of Q3 2026.

PharVision Advisers reported no remaining Quanterix position as of Q3 2026 after selling out during the quarter.
PharVision Advisers sold 13,039 Quanterix shares in Q3 2026, an estimated $56.3K.
PharVision Advisers first reported a position in Quanterix in Q3 2025 and held it in 2 quarters.
PharVision Advisers's Quanterix position peaked at $196K in Q3 2025.
35 funds tracked by Wall St. Rank held Quanterix as of Q3 2026.

Based on PharVision Advisers's 13F filing for Q3 2026, filed 29 Oct 2026.